About Matrilin-4
Matrilin-4 (MATN4) is a protein
from Homo sapiens identified by UniProt accession
O95460, 622 residues long.
MolForge cross-references it against 0 known binders and
30 disease associations.
Target properties
| Protein name | Matrilin-4 |
| UniProt accession | O95460 |
| Gene | MATN4 |
| Organism | Homo sapiens |
| Length | 622 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (30)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.37
- holoprosencephaly · score 0.29
- Global developmental delay · score 0.26
- Microcephaly · score 0.26
- Proptosis · score 0.26
- diabetes insipidus · score 0.26
- Meningomyelocele · score 0.26
- Seizure · score 0.26
- breast adenocarcinoma · score 0.20
- bipolar I disorder · score 0.20
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O95460-F1 | alphafold | PREDICTED | 82.04 | — |
Amino-acid sequence (622 residues)
MRGLLCWPVL LLLLQPWETQ LQLTGPRCHT GPLDLVFVID SSRSVRPFEF ETMRQFLMGL LRGLNVGPNA TRVGVIQYSS QVQSVFPLRA FSRREDMERA IRDLVPLAQG TMTGLAIQYA MNVAFSVAEG ARPPEERVPR VAVIVTDGRP QDRVAEVAAQ ARARGIEIYA VGVQRADVGS LRAMASPPLD EHVFLVESFD LIQEFGLQFQ SRLCGKDQCA EGGHGCQHQC VNAWAMFHCT CNPGYKLAAD NKSCLAIDLC AEGTHGCEHH CVNSPGSYFC HCQVGFVLQQ DQRSCRAIDY CSFGNHSCQH ECVSTPGGPR CHCREGHDLQ PDGRSCQVRD LCNGVDHGCE FQCVSEGLSY RCLCPEGRQL QADGKSCNRC REGHVDLVLL VDGSKSVRPQ NFELVKRFVN QIVDFLDVSP EGTRVGLVQF SSRVRTEFPL GRYGTAAEVK QAVLAVEYME RGTMTGLALR HMVEHSFSEA QGARPRALNV PRVGLVFTDG RSQDDISVWA ARAKEEGIVM YAVGVGKAVE AELREIASEP AELHVSYAPD FGTMTHLLEN LRGSICPEEG ISAGTELRSP CECESLVEFQ GRTLGALESL TLNLAQLTAR LEDLENQLAN QK
Explore Matrilin-4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets